Gregory Renza
Stock Analyst at Truist Securities
(3.36)
# 982
Out of 5,150 analysts
255
Total ratings
41.12%
Success rate
5.55%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Buy | $400 → $412 | $299.02 | +37.78% | 4 | Feb 27, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $145 → $152 | $148.22 | +2.55% | 3 | Feb 11, 2026 | |
| CGON CG Oncology | Maintains: Buy | $66 → $75 | $61.57 | +21.81% | 6 | Feb 10, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $820 → $818 | $787.50 | +3.87% | 3 | Feb 2, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $41 → $40 | $30.39 | +31.62% | 13 | Jan 8, 2026 | |
| AMGN Amgen | Maintains: Hold | $318 → $319 | $379.27 | -15.89% | 19 | Jan 8, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $59 → $60 | $34.68 | +73.01% | 14 | Jan 6, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $32 → $38 | $28.19 | +34.80% | 8 | Dec 24, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Buy | $14 → $18 | $8.35 | +115.57% | 5 | Dec 11, 2025 | |
| CATX Perspective Therapeutics | Assumes: Buy | $8 → $12 | $5.27 | +127.70% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $23 → $30 | $16.26 | +84.50% | 12 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $12.74 | +127.63% | 10 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $4.74 | +132.07% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $102.67 | +36.36% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $2.95 | +205.08% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $10 | $5.63 | +77.62% | 4 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $22.25 | +129.21% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $116.77 | +19.89% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $45 → $50 | $41.69 | +19.93% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $23.39 | +11.16% | 16 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $4.24 | +88.68% | 12 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $5 | $1.73 | +189.02% | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $182 → $172 | $188.69 | -8.85% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $113 → $38 | $57.54 | -34.83% | 14 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $7.12 | +68.54% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $5.81 | +140.96% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $22.86 | -21.26% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $1.42 | +3,280.28% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $110 → $20 | $5.33 | +275.23% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $0.96 | +1,558.89% | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $18.36 | +880.39% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $0.91 | +8,691.21% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.17 | +17,704.15% | 3 | Jun 2, 2020 |
BeOne Medicines AG
Feb 27, 2026
Maintains: Buy
Price Target: $400 → $412
Current: $299.02
Upside: +37.78%
Gilead Sciences
Feb 11, 2026
Maintains: Buy
Price Target: $145 → $152
Current: $148.22
Upside: +2.55%
CG Oncology
Feb 10, 2026
Maintains: Buy
Price Target: $66 → $75
Current: $61.57
Upside: +21.81%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Buy
Price Target: $820 → $818
Current: $787.50
Upside: +3.87%
Viridian Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $41 → $40
Current: $30.39
Upside: +31.62%
Amgen
Jan 8, 2026
Maintains: Hold
Price Target: $318 → $319
Current: $379.27
Upside: -15.89%
IDEAYA Biosciences
Jan 6, 2026
Maintains: Buy
Price Target: $59 → $60
Current: $34.68
Upside: +73.01%
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $28.19
Upside: +34.80%
Fulcrum Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $14 → $18
Current: $8.35
Upside: +115.57%
Perspective Therapeutics
Nov 24, 2025
Assumes: Buy
Price Target: $8 → $12
Current: $5.27
Upside: +127.70%
Nov 24, 2025
Assumes: Buy
Price Target: $23 → $30
Current: $16.26
Upside: +84.50%
Nov 24, 2025
Initiates: Buy
Price Target: $29
Current: $12.74
Upside: +127.63%
Nov 24, 2025
Initiates: Buy
Price Target: $11
Current: $4.74
Upside: +132.07%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $102.67
Upside: +36.36%
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $2.95
Upside: +205.08%
Nov 24, 2025
Initiates: Hold
Price Target: $10
Current: $5.63
Upside: +77.62%
Nov 24, 2025
Initiates: Buy
Price Target: $51
Current: $22.25
Upside: +129.21%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $116.77
Upside: +19.89%
Jul 8, 2025
Downgrades: Sector Perform
Price Target: $45 → $50
Current: $41.69
Upside: +19.93%
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $23.39
Upside: +11.16%
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $4.24
Upside: +88.68%
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $1.73
Upside: +189.02%
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $188.69
Upside: -8.85%
Apr 16, 2025
Maintains: Sector Perform
Price Target: $113 → $38
Current: $57.54
Upside: -34.83%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $7.12
Upside: +68.54%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $5.81
Upside: +140.96%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $22.86
Upside: -21.26%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $1.42
Upside: +3,280.28%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $110 → $20
Current: $5.33
Upside: +275.23%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $0.96
Upside: +1,558.89%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $18.36
Upside: +880.39%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $0.91
Upside: +8,691.21%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.17
Upside: +17,704.15%